The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Lennon, Frances E ^a   Mirzapoiazova, Tamara ^a   Mambetsariev, Bolot ^a   Poroyko, Valeriy A ^b   Salgia, Ravi ^a   Moss, Jonathan ^b   Singleton, Patrick A ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 1; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; FENTANYL; MORPHINE; MU OPIATE RECEPTOR; OPIATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE P60; PROTEIN ZO1; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT3 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; VIMENTIN; ANESTHETIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; NARCOTIC ANALGESIC AGENT;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNE CELL FUNCTION ASSAY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LUNG NON SMALL CELL CANCER; PATHOGENESIS; PHENOTYPE; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; CELL MOTION; DEFICIENCY; DISEASE COURSE; DRUG EFFECTS; GENETICS; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; TUMOR CELL LINE;

ANALGESICS, OPIOID; ANESTHETICS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE SILENCING; HUMANS; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 84899716869     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091577     Document Type: Article

References (75)

1. Bovill JG (2010) Surgery for cancer: does anesthesia matter? Anesth Analg 110: 1524-1526.
2. Snyder GL, Greenberg S (2010) Effect of anaesthetic technique and other perioperative factors on cancer recurrence. British journal of anaesthesia 105: 106-115.
3. Yeager MP, Rosenkranz KM (2010) Cancer recurrence after surgery: a role for regional anesthesia? Regional anesthesia and pain medicine 35: 483-484.
4. Lennon FE, Moss J, Singleton PA (2012) The mu-opioid receptor in cancer progression: is there a direct effect? Anesthesiology 116: 940-945.
5. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, et al. (2008) Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 109: 180-187.
6. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI (2006) Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 105: 660-664. (Pubitemid 44477309)
7. Christopherson R, James KE, Tableman M, Marshall P, Johnson FE (2008) Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg 107: 325-332.
8. Myles PS, Peyton P, Silbert B, Hunt J, Rigg JR, et al. (2011) Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ 342: d1491.
9. Tavare AN, Perry NJ, Benzonana LL, Takata M, Ma D (2011) Cancer recurrence after surgery: Direct and indirect effects of anesthetic agents*. International journal of cancer Journal international du cancer.
10. Afsharimani B, Cabot PJ, Parat MO (2011) Morphine use in cancer surgery. Frontiers in pharmacology 2: 46.
11. Afsharimani B, Cabot P, Parat MO (2011) Morphine and tumor growth and metastasis. Cancer metastasis reviews 30: 225-238.
12. Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, et al. (2011) The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesthesia and analgesia 112: 558-567.
13. Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, et al. (2012) Overexpression of the mu-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology 116: 857-867.
14. Spiro SG, Tanner NT, Silvestri GA, Janes SM, Lim E, et al. (2010) Lung cancer: progress in diagnosis, staging and therapy. Respirology 15: 44-50.
15. Stinchcombe TE, Bogart J, Veeramachaneni NK, Kratzke R, Govindan R (2011) Annual review of advances in non-small cell lung cancer research: a report for the year 2010. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 6: 1443-1450.
16. Denlinger CE, Ikonomidis JS, Reed CE, Spinale FG (2010) Epithelial to mesenchymal transition: the doorway to metastasis in human lung cancers. The Journal of thoracic and cardiovascular surgery 140: 505-513.
17. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, et al. (2010) Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer science 101: 293-299.
18. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. The Journal of clinical investigation 119: 1420-1428.
19. Voulgari A, Pintzas A (2009) Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochimica et biophysica acta 1796: 75-90.
20. Cannito S, Novo E, Valfre di Bonzo L, Busletta C, Colombatto S, et al. (2009) Epithelial-Mesenchymal Transition: from Molecular Mechanisms, Redox Regulation to Implications in Human Health and Disease. Antioxid Redox Signal.
21. Chow G, Tauler J, Mulshine JL (2010) Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer. J Biomed Biotechnol: 485468.
22. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
23. Charpidou A, Blatza D, Anagnostou V, Syrigos KN (2008) Review. EGFR mutations in non-small cell lung cancer-clinical implications. In vivo 22: 529-536.
24. Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, et al. (2011) EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 71: 241-243.
25. Holz C, Niehr F, Boyko M, Hristozova T, Distel L, et al. (2011) Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 101: 158-164.
26. Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T, et al. (2010) Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer research 30: 2513-2517.
27. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, et al. (2009) Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. British journal of cancer 100: 134-144.
28. Carlson JJ (2009) Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence. Expert review of pharmacoeconomics & outcomes research 9: 409-416.
29. Choi EJ, Ryu YK, Kim SY, Wu HG, Kim JS, et al. (2010) Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response. Molecular cancer research : MCR 8: 1027-1036.
30. Ganjoo KN, Wakelee H (2007) Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics : targets & therapy 1: 335-346.
31. Gridelli C, Morabito A, Gebbia V, Mencoboni M, Carrozza F, et al. (2010) Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer 67: 86-92.
32. De Greve J, Decoster L, Van Meerbeek J, Vermeij J, Teugels E, et al. (2008) [Targeted therapies in the treatment of non-small cell lung cancer]. Bull Cancer 95: 358-364.
33. Ng R, Loreto M, Lee R, Leighl NB (2008) Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. Lung Cancer 61: 262-265.
34. Subramanian J, Madadi AR, Dandona M, Williams K, Morgensztern D, et al. (2010) Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.gov website. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 5: 1116-1119.
35. Fujioka N, Nguyen J, Chen C, Li Y, Pasrija T, et al. (2011) Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesthesia and analgesia 113: 1353-1364.
36. Giubellino A, Burke TR, Jr., Bottaro DP (2008) Grb2 signaling in cell motility and cancer. Expert opinion on therapeutic targets 12: 1021-1033.
37. Kiyatkin A, Aksamitiene E, Markevich NI, Borisov NM, Hoek JB, et al. (2006) Scaffolding protein Grb2-associated binder 1 sustains epidermal growth factor-induced mitogenic and survival signaling by multiple positive feedback loops. The Journal of biological chemistry 281: 19925-19938. (Pubitemid 44065766)
38. Vogt PK, Hart JR (2011) PI3K and STAT3: a new alliance. Cancer discovery 1: 481-486.
39. Hart JR, Liao L, Yates JR, 3rd, Vogt PK (2011) Essential role of Stat3 in PI3K-induced oncogenic transformation. Proceedings of the National Academy of Sciences of the United States of America 108: 13247-13252.
40. Chan PC, Chen YL, Cheng CH, Yu KC, Cary LA, et al. (2003) Src phosphorylates Grb2-associated binder 1 upon hepatocyte growth factor stimulation. The Journal of biological chemistry 278: 44075-44082. (Pubitemid 37377148)
41. Akca H, Tani M, Hishida T, Matsumoto S, Yokota J (2006) Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. Lung Cancer 54: 25-33.
42. Hanada M, Feng J, Hemmings BA (2004) Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 1697: 3-16. (Pubitemid 38326757)
43. Singleton PA, Moss J (2010) Effect of perioperative opioids on cancer recurrence: a hypothesis. Future oncology 6: 1237-1242.
44. Maione P, Rossi A, Sacco PC, Bareschino MA, Schettino C, et al. (2010) Advances in chemotherapy in advanced non-small-cell lung cancer. Expert opinion on pharmacotherapy 11: 2997-3007.
45. Beland MD, Wasser EJ, Mayo-Smith WW, Dupuy DE (2010) Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology 254: 301-307.
46. Belcheva MM, Szucs M, Wang D, Sadee W, Coscia CJ (2001) mu-Opioid receptor-mediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation. The Journal of biological chemistry 276: 33847-33853.
47. Belcheva MM, Tan Y, Heaton VM, Clark AL, Coscia CJ (2003) Mu opioid transactivation and down-regulation of the epidermal growth factor receptor in astrocytes: implications for mitogen-activated protein kinase signaling. Molecular pharmacology 64: 1391-1401. (Pubitemid 37532229)
48. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, et al. (1999) EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402: 884-888.
49. Gridelli C, Rossi A, Bareschino MA, Schettino C, Sacco PC, et al. (2010) The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Expert opinion on investigational drugs 19: 631-639.
50. Gualberto A, Karp DD (2009) Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clinical lung cancer 10: 273-280.
51. Yin M, Guan X, Liao Z, Wei Q (2009) Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. American journal of translational research 1: 101-114.
52. Nishida K, Hirano T (2003) The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors. Cancer science 94: 1029-1033. (Pubitemid 38035515)
53. Singleton PA, Mambetsariev N, Lennon FE, Mathew B, Siegler JH, et al. (2010) Methylnaltrexone Potentiates the Anti-Angiogenic Effects of mTOR Inhibitors. J Angiogenes Res 2: 5.
54. Schaeper U, Gehring NH, Fuchs KP, Sachs M, Kempkes B, et al. (2000) Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. The Journal of cell biology 149: 1419-1432. (Pubitemid 30437616)
55. Devarajan E, Huang S (2009) STAT3 as a central regulator of tumor metastases. Curr Mol Med 9: 626-633.
56. Yin ZJ, Jin FG, Liu TG, Fu EQ, Xie YH, et al. (2010) Overexpression of STAT3 Potentiates Growth, Survival, and Radioresistance of Non-Small-Cell Lung Cancer (NSCLC) cells. The Journal of surgical research.
57. Lim CP, Cao X (2006) Structure, function, and regulation of STAT proteins. Molecular bioSystems 2: 536-550. (Pubitemid 44583902)
58. Debruyne D, Leroy A, O DEW, Vakaet L, Mareel M, et al. (2010) Direct effects of delta opioid receptor agonists on invasion-associated activities of HCT-8/E11 colon cancer cells. Anticancer research 30: 9-17.
59. Lee MW, Kim DS, Lee JH, Lee BS, Lee SH, et al. (2011) The roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth and migration. Cancer science.
60. Kandel ES, Hay N (1999) The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 253: 210-229.
61. Pene F, Claessens YE, Muller O, Viguie F, Mayeux P, et al. (2002) Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21: 6587-6597. (Pubitemid 35177037)
62. Singleton PA, Mambetsariev N, Lennon FE, Mathew B, Siegler JH, et al. (2010) Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. Journal of angiogenesis research 2: 5.
63. Singleton PA, Garcia JG, Moss J (2008) Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Molecular cancer therapeutics 7: 1669-1679.
64. Xu J, Xu M, Hurd YL, Pasternak GW, Pan YX (2009) Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene. Journal of neurochemistry 108: 962-972.
65. Lee K, Nelson CM (2012) New insights into the regulation of epithelial-mesenchymal transition and tissue fibrosis. International review of cell and molecular biology 294: 171-221.
66. Frank JW, Bair MJ, Becker WC, Krebs EE, Liebschutz JM, et al. (2014) Update in Pain Medicine for Primary Care Providers: A Narrative Review, 2010-2012. Pain medicine.
67. Mercadante S (2014) Managing difficult pain conditions in the cancer patient. Current pain and headache reports 18: 395.
68. Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo EM, Park SY, et al. (2013) Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer. Cancer research 73: 6424-6434.
69. Aicher SA, Punnoose A, Goldberg A (2000) mu-Opioid receptors often colocalize with the substance P receptor (NK1) in the trigeminal dorsal horn. The Journal of neuroscience : the official journal of the Society for Neuroscience 20: 4345-4354.
70. Pfeiffer M, Kirscht S, Stumm R, Koch T, Wu D, et al. (2003) Heterodimerization of substance P and mu-opioid receptors regulates receptor trafficking and resensitization. The Journal of biological chemistry 278: 51630-51637. (Pubitemid 38020408)
71. Illing S, Mann A, Schulz S (2013) Heterologous Regulation of Agonist-Independent mu-Opioid Receptor Phosphorylation by Protein Kinase C. British journal of pharmacology.
72. Yu YJ, Arttamangkul S, Evans CJ, Williams JT, von Zastrow M (2009) Neurokinin 1 receptors regulate morphine-induced endocytosis and desensitization of mu-opioid receptors in CNS neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience 29: 222-233.
73. Perez S, Tierney A, Deniau JM, Kemel ML (2007) Tachykinin regulation of cholinergic transmission in the limbic/prefrontal territory of the rat dorsal striatum: implication of new neurokinine 1-sensitive receptor binding site and interaction with enkephalin/mu opioid receptor transmission. Journal of neurochemistry 103: 2153-2163. (Pubitemid 350173578)
74. Bigliardi-Qi M, Gaveriaux-Ruff C, Pfaltz K, Bady P, Baumann T, et al. (2007) Deletion of mu- and kappa-opioid receptors in mice changes epidermal hypertrophy, density of peripheral nerve endings, and itch behavior. The Journal of investigative dermatology 127: 1479-1488. (Pubitemid 46762967)
75. Wan Q, Douglas SD, Wang X, Kolson DL, O'Donnell LA, et al. (2006) Morphine upregulates functional expression of neurokinin-1 receptor in neurons. Journal of neuroscience research 84: 1588-1596. (Pubitemid 44683152)